Nearly half of patients with the most common form of adult leukemia may have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment.
Patients with terminal forms of leukemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects.
A German study of a new drug therapy for chronic lymphocytic leukemia was praised because the majority of the patients enrolled were elderly and had other, coexisting health issues.
The largest clinical study ever conducted to date of patients with advanced leukemia found that 88% achieved complete remission after being treated with genetically modified versions of their own immune cells.
A group of researchers discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|